The HER2-targeted therapy drugs, including monoclonal antibody-based regimens, trastuzumab, and pertuzumab, have substantially improved progression-free and overall survival in patients with HER2-positive breast cancer [3–5]. The gene discussed is ERBB2; the disease is breast carcinoma.